Vestcor Inc Sells 9,299 Shares of Halozyme Therapeutics, Inc. $HALO

Vestcor Inc lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 21.7% in the 4th quarter, Holdings Channel reports. The firm owned 33,512 shares of the biopharmaceutical company’s stock after selling 9,299 shares during the quarter. Vestcor Inc’s holdings in Halozyme Therapeutics were worth $2,255,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Clark Capital Management Group Inc. lifted its position in shares of Halozyme Therapeutics by 14.4% during the 3rd quarter. Clark Capital Management Group Inc. now owns 202,965 shares of the biopharmaceutical company’s stock worth $14,885,000 after purchasing an additional 25,582 shares during the last quarter. Intech Investment Management LLC grew its holdings in Halozyme Therapeutics by 46.0% in the 3rd quarter. Intech Investment Management LLC now owns 148,667 shares of the biopharmaceutical company’s stock valued at $10,903,000 after buying an additional 46,850 shares during the last quarter. Allworth Financial LP grew its holdings in Halozyme Therapeutics by 322.5% in the 3rd quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company’s stock valued at $2,914,000 after buying an additional 30,331 shares during the last quarter. ING Groep NV bought a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $6,652,000. Finally, Element Squared LLC bought a new position in Halozyme Therapeutics in the 4th quarter worth approximately $1,193,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on HALO. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Wells Fargo & Company raised their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. Morgan Stanley reduced their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Finally, UBS Group reissued a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday. Eight research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $81.60.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $71.53 on Monday. Halozyme Therapeutics, Inc. has a 52-week low of $51.06 and a 52-week high of $82.22. The firm has a market capitalization of $8.48 billion, a PE ratio of 25.73, a price-to-earnings-growth ratio of 0.30 and a beta of 0.88. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The company’s fifty day moving average price is $66.79 and its two-hundred day moving average price is $68.72.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.06. The business had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm’s revenue was up 42.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, analysts expect that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised Halozyme’s earnings estimates across multiple future periods, including FY2026, FY2027, and FY2028, signaling confidence in the company’s longer-term profit growth. Halozyme Therapeutics article
• Positive Sentiment: Analysts also increased estimates for several individual quarters in 2027, reinforcing a constructive earnings outlook for Halozyme Therapeutics. Halozyme Therapeutics article
• Neutral Sentiment: One near-term forecast was trimmed slightly and another was revised lower, but the overall analyst tone remains mostly favorable. Halozyme Therapeutics article
• Neutral Sentiment: Recent insider selling by the CEO was disclosed, but the trades were executed under a pre-arranged trading plan, which typically lessens investor concern. Halozyme Therapeutics article

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, COO Cortney Caudill sold 8,857 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total transaction of $599,087.48. Following the completion of the transaction, the chief operating officer directly owned 7,055 shares in the company, valued at $477,200.20. This represents a 55.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $66.21, for a total value of $107,591.25. Following the transaction, the director directly owned 43,669 shares of the company’s stock, valued at approximately $2,891,324.49. The trade was a 3.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 102,107 shares of company stock valued at $6,898,834. 2.50% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.